Results announcement for the second quarter 2012
Posted: 25 July 2012 | | No comments yet
GSK delivers Q2 core EPS of 26.4p and dividend of 17p…


- Core EPS of 26.4p and dividend of 17p
- Pharma and Vaccines sales in EMAP +9%, Japan +6%
- Consumer Healthcare sales +7% (excluding divested brands & alli)
- Pharma & Vaccines sales in Europe (-8%) & US (-6%) reflecting challenging macro-economy & continued transition of product portfolio
- Full year sales now expected to be in line with 2011
Full announcement with CEO and CFO videos available in the Investors section of this website: http://www.gsk.com/investors/quarterly_results.htm.